Custirsen

Shares of OncoGenex Pharmaceuticals Inc (NASDAQ: OGXI) plunged more than 30 percent on Wednesday. OncoGenex said that its Phase 3 AFFINITY trial with custirsen is continuing following an interim analysis. Stephen Willey of Stifel downgraded shares of OncoGenex to Hold despite shares trading at/...